Registrati gratuitamente per ottenere quotazioni in tempo reale, grafici interattivi, flusso di opzioni in tempo reale e altro ancora.
| Data | Nome del titolare | Azioni transazionate | Intervallo di valore ($) | Tipo di transazione | Intervallo di prezzo ($) | Azioni a fine dichiarazione | % di variazione |
|---|---|---|---|---|---|---|---|
| 2026-05-21 | Mr. Qingqing YiIndependent Non-Executive Director and Member of Scientific Advisory Committee | 10,99k | 0,00 | Derivative Exercise and Retained Stock | - | 27,33k | 67,22% |
| 2026-06-01 | Mr. Qingqing YiIndependent Non-Executive Director and Member of Scientific Advisory Committee | -235,00 | 65,60k | Vendita | 279,13 | 0,00 | -100,00% |
| 2026-05-21 | Dr. Margaret Han DuganMember of SA, Commercial & Medical Affairs Advisory Committee and Independent Non-Exec. Director | 10,99k | 0,00 | Derivative Exercise and Retained Stock | - | 56,94k | 23,90% |
| 2026-05-21 | Dr. Alessandro RivaCo-Chairman of Scientific Advisory Committee & Director | 10,99k | 0,00 | Derivative Exercise and Retained Stock | - | 56,94k | 23,90% |
| 2026-05-21 | Dr. Corazon Dating SandersIndependent Non-Executive Director and Member of Commercial & Medical Affairs Advis. & SA Committee | 10,99k | 0,00 | Derivative Exercise and Retained Stock | - | 57,23k | 23,76% |
| 2026-05-22 | Dr. Alessandro RivaCo-Chairman of Scientific Advisory Committee & Director | -212,00 | 65,62k | Vendita | 309,51 | 0,00 | -100,00% |
| 2026-05-22 | Dr. Margaret Han DuganMember of SA, Commercial & Medical Affairs Advisory Committee and Independent Non-Exec. Director | -212,00 | 65,64k | Vendita | 309,60 | 0,00 | -100,00% |
| 2026-05-22 | Dr. Corazon Dating SandersIndependent Non-Executive Director and Member of Commercial & Medical Affairs Advis. & SA Committee | -212,00 | 65,63k | Vendita | 309,59 | 0,00 | -100,00% |
| 2026-05-22 | Mr. Ranjeev KrishanaMember of Commercial & Medical Affairs Advisory Committee and Independent Lead Director | -2,76k | 65,57k | Vendita | 23,79 | 71,27k | -3,72% |
| 2026-05-22 | Mr. Michael J. GollerIndependent Non-Executive Director & Member of the Scientific Advisory Committee | -2,74k | 65,42k | Vendita | 23,85 | 71,28k | -3,71% |
| 2026-05-21 | Mr. Ranjeev KrishanaMember of Commercial & Medical Affairs Advisory Committee and Independent Lead Director | 10,99k | 0,00 | Derivative Exercise and Retained Stock | - | 74,02k | 17,43% |
| 2026-05-21 | Mr. Michael J. GollerIndependent Non-Executive Director & Member of the Scientific Advisory Committee | 10,99k | 0,00 | Derivative Exercise and Retained Stock | - | 74,02k | 17,43% |
| 2026-05-20 | Capital Research and Management CompanySocietà | 72,54k | 21,91M | Acquisto | 302,13 | 6,54M | 1,12% |
| 2026-05-13 | Mr. Chan LeeGeneral Counsel, Senior VP & Corporate Secretary | -332,00 | 39,56k | Derivative Exercise and Sale | 159,03 - 310,72 | 0,00 | - |
| 2026-05-07 | JPMorgan Chase & Co.Società | 406,08k | 9,85M | Acquisto | 24,26 | 23,19k | -106,06% |
| 2026-05-05 | JPMorgan Chase & Co.Società | -706,53k | 15,88M | Vendita | 22,47 | 119,23k | -85,56% |
| 2026-04-08 | Mr. Chan LeeGeneral Counsel, Senior VP & Corporate Secretary | -332,00 | 39,85k | Derivative Exercise and Sale | 159,03 - 311,59 | 0,00 | - |
| 2026-03-11 | Mr. Chan LeeGeneral Counsel, Senior VP & Corporate Secretary | -341,00 | 36,95k | Derivative Exercise and Sale | 159,03 - 300,00 | 0,00 | - |
| 2026-02-04 | Mr. Chan LeeGeneral Counsel, Senior VP & Corporate Secretary | -1,66k | 262,48k | Derivative Exercise and Sale | 159,03 - 350,00 | 0,00 | - |
| 2026-02-03 | JPMorgan Chase & Co.Società | 1,04M | 27,38M | Acquisto | 26,23 | 2,26M | 85,78% |
| 2026-01-15 | JPMorgan Chase & Co.Società | 35,57k | 938,72k | Acquisto | 26,39 | 236,26k | 17,73% |
| 2026-01-15 | JPMorgan Chase & Co.Società | 1,55M | 40,93M | Acquisto | 26,39 | 2,36M | 191,64% |
| 2026-01-15 | JPMorgan Chase & Co.Società | -191,33k | 5,05M | Vendita | 26,39 | 2,36M | -7,50% |
| 2026-01-16 | JPMorgan Chase & Co.Società | 28,69k | 746,29k | Acquisto | 26,01 | 253,90k | 12,74% |
| 2026-01-16 | JPMorgan Chase & Co.Società | -117,00 | 3,04k | Vendita | 26,01 | 253,90k | -0,05% |
| 2026-01-16 | JPMorgan Chase & Co.Società | -1,67M | 43,53M | Vendita | 26,01 | 711,32k | -70,17% |
| 2026-01-14 | JP Morgan Asset ManagementSocietà | -3,90k | 103,29k | Vendita | 26,48 | 55,92k | -6,52% |
| 2026-01-14 | JPMorgan Chase & Co.Società | 9,25k | 245,09k | Acquisto | 26,48 | 202,24k | 4,80% |
| 2026-01-14 | JPMorgan Chase & Co.Società | -4,89k | 129,46k | Vendita | 26,48 | 202,24k | -2,36% |
| 2026-01-14 | JPMorgan Chase & Co.Società | 167,86k | 4,45M | Acquisto | 26,48 | 783,04k | 27,29% |
| 2026-01-14 | JPMorgan Chase & Co.Società | -1,94M | 51,30M | Vendita | 26,48 | 783,04k | -71,21% |
| 2026-01-08 | JPMorgan Chase & Co.Società | -546,40k | 0,00 | Other Disposition | - | 769,48k | -41,52% |
| 2026-01-07 | Mr. Chan LeeGeneral Counsel, Senior VP & Corporate Secretary | -664,00 | 93,09k | Derivative Exercise and Sale | 159,03 - 331,76 | 0,00 | - |
| 2025-12-31 | Mr. Anthony C. HooperChairman of Commercial & Medical Affairs Advisory Committee and Ind. Non Executive Director | 12,92k | 0,00 | Derivative Exercise and Retained Stock | - | 37,41k | 52,76% |
| 2025-12-19 | JPMorgan Chase & Co.Società | -140,55k | 0,00 | Other Disposition | - | 798,45k | -14,97% |
| 2025-12-16 | JPMorgan Chase & Co.Società | -762,99k | 0,00 | Other Disposition | - | 258,01k | -74,73% |
| 2025-12-16 | JPMorgan Chase & Co.Società | -15,81k | 0,00 | Other Disposition | - | 1,79M | -0,88% |
| 2025-12-15 | JPMorgan Chase & Co.Società | -598,45k | 0,00 | Other Disposition | - | 1,47M | -28,86% |
| 2025-12-11 | JP Morgan Asset ManagementSocietà | -500,00 | 0,00 | Other Disposition | - | -500,00 | - |
| 2025-12-11 | JPMorgan Chase & Co.Società | -171,98k | 0,00 | Other Disposition | - | 1,04M | -14,20% |
| 2025-12-15 | Mr. John V. OylerCo-Founder, Executive Chairman & CEO | -100,00k | 30,66M | Automatic Disposition | 300,80 - 314,92 | 0,00 | -100,00% |
| 2025-12-10 | JPMorgan Chase & Co.Società | -508,02k | 0,00 | Other Disposition | - | 1,40M | -26,65% |
| 2025-12-10 | Mr. Chan LeeGeneral Counsel, Senior VP & Corporate Secretary | -664,00 | 86,37k | Derivative Exercise and Sale | 159,03 - 325,00 | 0,00 | - |
| 2025-11-26 | Dr. Corazon Dating SandersIndependent Non-Executive Director and Member of Commercial & Medical Affairs Advis. & SA Committee | -2,63k | 477,76k | Derivative Exercise and Sale | 159,03 - 342,47 | 0,00 | - |
| 2025-11-13 | JPMorgan Chase & Co.Società | -771,57k | 0,00 | Other Disposition | - | 2,48M | -23,73% |
| 2025-11-17 | Dr. Xiaobin WuInsider | -3,99k | 1,52M | Vendita | 380,23 - 382,32 | 16,37k | -19,61% |
| 2025-11-12 | Dr. Xiaobin WuInsider | -16,01k | 5,85M | Vendita | 350,44 - 381,05 | 16,37k | -49,45% |
| 2025-11-12 | Mr. Chan LeeGeneral Counsel, Senior VP & Corporate Secretary | -996,00 | 157,07k | Derivative Exercise and Sale | 159,03 - 350,00 | 0,00 | - |
| 2025-11-11 | Mr. John V. OylerCo-Founder, Executive Chairman & CEO | -1,01M | 0,00 | Other Disposition | - | 51,48M | -1,92% |
| 2025-11-07 | Dr. Xiaodong WangCo-Chairman of Scientific Advisory Board, Non-Executive Director & Co-Founder | -424,07k | 0,00 | Other Disposition | - | 9,32M | -4,35% |
| 2025-10-21 | JPMorgan Chase & Co.Società | -9,47k | 0,00 | Other Disposition | - | 1,59M | -0,59% |
| 2025-10-15 | JPMorgan Chase & Co.Società | -22,95k | 0,00 | Other Disposition | - | 270,26k | -7,83% |
| 2025-10-15 | JPMorgan Chase & Co.Società | -136,97k | 0,00 | Other Disposition | - | 1,54M | -8,19% |
| 2025-10-14 | JPMorgan Chase & Co.Società | -97,34k | 0,00 | Other Disposition | - | 271,74k | -26,37% |
| 2025-10-14 | JPMorgan Chase & Co.Società | -1,60k | 0,00 | Other Disposition | - | 1,54M | -0,10% |
| 2025-10-13 | JPMorgan Chase & Co.Società | -615,48k | 0,00 | Other Disposition | - | 1,52M | -28,79% |
| 2025-10-08 | Mr. Chan LeeGeneral Counsel, Senior VP & Corporate Secretary | -9,56k | 1,33M | Derivative Exercise and Sale | 159,03 - 351,12 | - | - |
| 2025-10-08 | Mr. Chan LeeGeneral Counsel, Senior VP & Corporate Secretary | -1,11k | 389,20k | Automatic Disposition | 350,00 | 0,00 | -100,00% |
| 2025-09-22 | JPMorgan Chase & Co.Società | -35,06k | 0,00 | Other Disposition | - | 277,27k | -11,23% |
| 2025-09-22 | JPMorgan Chase & Co.Società | -399,98k | 0,00 | Other Disposition | - | 2,06M | -16,24% |
| 2025-09-17 | JPMorgan Chase & Co.Società | -24,28k | 0,00 | Other Disposition | - | 274,35k | -8,13% |
| 2025-09-17 | JPMorgan Chase & Co.Società | -346,93k | 0,00 | Other Disposition | - | 1,95M | -15,10% |
| 2025-09-16 | Mr. John V. OylerCo-Founder, Executive Chairman & CEO | -27,80k | 9,06M | Automatic Disposition | 324,12 - 327,78 | 0,00 | -100,00% |
| 2025-09-12 | JPMorgan Chase & Co.Società | -671,57k | 0,00 | Other Disposition | - | 1,75M | -27,70% |
| 2025-09-10 | Mr. Chan LeeGeneral Counsel, Senior VP & Corporate Secretary | -8,89k | 1,14M | Derivative Exercise and Sale | 159,03 - 327,93 | 0,00 | - |
| 2025-09-10 | Mr. Chan LeeGeneral Counsel, Senior VP & Corporate Secretary | -1,11k | 361,40k | Automatic Disposition | 325,00 | 0,00 | -100,00% |
| 2025-09-09 | JPMorgan Chase & Co.Società | -208,12k | 0,00 | Other Disposition | - | 1,73M | -10,76% |
| 2025-09-09 | Dr. Xiaodong WangCo-Chairman of Scientific Advisory Board, Non-Executive Director & Co-Founder | -148,10k | 0,00 | Other Disposition | - | 9,74M | -1,50% |
| 2025-09-09 | Mr. Wang LaiPresident and Global Head of Research & Development | -5,00k | 1,75M | Automatic Disposition | 350,06 | 0,00 | -100,00% |
| 2025-09-09 | Capital Research and Management CompanySocietà | 67,88k | 3,03M | Acquisto | 44,70 | 5,32M | 1,29% |
| 2025-09-05 | Dr. Corazon Dating SandersIndependent Non-Executive Director and Member of Commercial & Medical Affairs Advis. & SA Committee | -2,67k | 483,22k | Derivative Exercise and Sale | 155,68 - 337,00 | 0,00 | - |
| 2025-09-02 | Mr. Titus B. BallVP & CAO | -122,00 | 39,86k | Vendita | 326,76 | 0,00 | -100,00% |
| 2025-08-13 | Dr. Xiaobin WuInsider | -89,79k | 12,91M | Derivative Exercise and Sale | 155,68 - 308,03 | 16,37k | - |
| 2025-08-13 | Mr. Chan LeeGeneral Counsel, Senior VP & Corporate Secretary | -8,23k | 1,01M | Derivative Exercise and Sale | 159,03 - 301,00 | 0,00 | - |
| 2025-08-13 | Mr. Chan LeeGeneral Counsel, Senior VP & Corporate Secretary | -2,78k | 836,57k | Automatic Disposition | 300,00 - 301,00 | 0,00 | -100,00% |
| 2025-08-11 | Capital Research and Management CompanySocietà | -55,08k | 15,89M | Vendita | 288,52 | 5,21M | -1,05% |
| 2025-08-01 | Mr. Aaron RosenbergCFO | -1,19k | 345,66k | Vendita | 290,47 | 0,00 | -100,00% |
| 2025-07-29 | Mr. Wang LaiPresident and Global Head of Research & Development | -4,30k | 1,30M | Automatic Disposition | 302,00 - 305,00 | 0,00 | -100,00% |
| 2025-07-30 | Mr. Chan LeeGeneral Counsel, Senior VP & Corporate Secretary | -920,00 | 280,23k | Vendita | 304,60 | 0,00 | -100,00% |
| 2025-07-18 | Mr. Wang LaiPresident and Global Head of Research & Development | -700,00 | 210,00k | Automatic Disposition | 300,00 | 0,00 | -100,00% |
| 2025-07-17 | JPMorgan Chase & Co.Società | -794,20k | 0,00 | Other Disposition | - | 1,29M | -38,16% |
| 2025-07-09 | Mr. John V. OylerCo-Founder, Executive Chairman & CEO | -27,80k | 7,04M | Automatic Disposition | 252,23 - 254,83 | 0,00 | -100,00% |
| 2025-06-23 | JPMorgan Chase & Co.Società | -1,45M | 0,00 | Other Disposition | - | 1,30M | -52,81% |
| 2025-06-23 | Mr. Wang LaiPresident and Global Head of Research & Development | -1,03k | 267,28k | Vendita | 260,00 | 0,00 | -100,00% |
| 2025-06-23 | Dr. Xiaobin WuInsider | -1,36k | 354,38k | Vendita | 260,00 | 16,37k | -7,69% |
| 2025-06-24 | Dr. Xiaodong WangCo-Chairman of Scientific Advisory Board, Non-Executive Director & Co-Founder | -2,01k | 532,87k | Automatic Disposition | 263,50 - 267,81 | 0,00 | -100,00% |
| 2025-06-23 | Mr. John V. OylerCo-Founder, Executive Chairman & CEO | -3,17k | 830,36k | Vendita | 261,57 - 262,90 | 0,00 | -100,00% |
| 2025-06-16 | JPMorgan Chase & Co.Società | -76,65k | 0,00 | Other Disposition | - | 418,02k | -15,49% |
| 2025-06-16 | JPMorgan Chase & Co.Società | -1,05M | 0,00 | Other Disposition | - | 1,96M | -34,91% |
| 2025-06-16 | Mr. Chan LeeGeneral Counsel, Senior VP & Corporate Secretary | -422,00 | 112,46k | Vendita | 266,50 | 0,00 | -100,00% |
| 2025-06-16 | Mr. Wang LaiPresident and Global Head of Research & Development | -1,65k | 431,70k | Vendita | 251,37 - 266,40 | 0,00 | -100,00% |
| 2025-06-16 | Dr. Xiaobin WuInsider | -2,17k | 567,74k | Vendita | 250,87 - 266,22 | 16,37k | -11,72% |
| 2025-06-17 | Mr. John V. OylerCo-Founder, Executive Chairman & CEO | -1,46k | 374,47k | Vendita | 256,49 | 0,00 | -100,00% |
| 2025-06-16 | Mr. John V. OylerCo-Founder, Executive Chairman & CEO | -3,68k | 979,05k | Vendita | 266,05 | 0,00 | -100,00% |
| 2025-06-13 | JPMorgan Chase & Co.Società | -77,70k | 0,00 | Other Disposition | - | 1,87M | -3,98% |
| 2025-06-12 | JP Morgan Asset ManagementSocietà | 91,00 | 1,94k | Acquisto | 21,37 | 254,14k | 0,04% |
| 2025-06-12 | JPMorgan Chase & Co.Società | 624,00 | 13,33k | Acquisto | 21,37 | 275,64k | 0,23% |
| 2025-06-12 | JPMorgan Chase & Co.Società | -3,71k | 79,16k | Vendita | 21,37 | 275,64k | -1,33% |
| 2025-06-12 | JPMorgan Chase & Co.Società | -19,14k | 0,00 | Other Disposition | - | 275,64k | -6,49% |
| 2025-06-12 | JPMorgan Chase & Co.Società | 1,11M | 23,75M | Acquisto | 21,37 | 1,27M | 694,17% |
| 2025-06-12 | JPMorgan Chase & Co.Società | -991,15k | 0,00 | Other Disposition | - | 1,27M | -43,80% |
| 2025-06-11 | JPMorgan Chase & Co.Società | -111,66k | 0,00 | Other Disposition | - | 297,86k | -27,27% |
| 2025-06-10 | JP Morgan Asset ManagementSocietà | 535,00 | 10,92k | Acquisto | 20,40 | 254,05k | 0,21% |
| 2025-06-10 | JPMorgan Chase & Co.Società | 50,87k | 1,04M | Acquisto | 20,40 | 285,41k | 21,69% |
| 2025-06-10 | JPMorgan Chase & Co.Società | -32,29k | 658,78k | Vendita | 20,40 | 285,41k | -10,16% |
| 2025-06-10 | JPMorgan Chase & Co.Società | 234,40k | 4,78M | Acquisto | 20,40 | 883,08k | 36,14% |
| 2025-06-10 | JPMorgan Chase & Co.Società | -293,45k | 5,99M | Vendita | 20,40 | 883,08k | -24,94% |
| 2025-06-10 | 55I, LLCSocietà | -13,00 | 265,25 | Vendita | 20,40 | 13,00 | -50,00% |
| 2025-06-11 | Mr. Titus B. BallVP & CAO | -134,00 | 34,62k | Vendita | 258,36 | 0,00 | -100,00% |
| 2025-06-10 | Dr. Xiaodong WangCo-Chairman of Scientific Advisory Board, Non-Executive Director & Co-Founder | -41,76k | 10,70M | Derivative Exercise and Sale | 6,50 - 264,85 | 0,00 | - |
| 2025-06-10 | Mr. Qingqing YiIndependent Non-Executive Director and Member of Scientific Advisory Committee | -29,61k | 0,00 | Other Disposition | - | - | - |
| 2025-06-09 | JP Morgan Asset ManagementSocietà | -8,10k | 166,22k | Vendita | 20,52 | 117,50k | -6,45% |
| 2025-06-09 | JPMorgan Chase & Co.Società | 33,24k | 682,15k | Acquisto | 20,52 | 305,52k | 12,21% |
| 2025-06-09 | JPMorgan Chase & Co.Società | -32,45k | 0,00 | Other Disposition | - | 305,52k | -9,60% |
| 2025-06-09 | JPMorgan Chase & Co.Società | 834,32k | 17,12M | Acquisto | 20,52 | 941,77k | 776,41% |
| 2025-06-09 | JPMorgan Chase & Co.Società | -841,00k | 0,00 | Other Disposition | - | 941,77k | -47,17% |
| 2025-06-06 | JP Morgan Asset ManagementSocietà | 65,00 | 1,28k | Acquisto | 19,64 | 253,51k | 0,03% |
| 2025-06-06 | JPMorgan Chase & Co.Società | 30,99k | 608,52k | Acquisto | 19,64 | 304,73k | 11,32% |
| 2025-06-06 | JPMorgan Chase & Co.Società | -7,15k | 140,41k | Vendita | 19,64 | 304,73k | -2,29% |
| 2025-06-06 | JPMorgan Chase & Co.Società | 215,30k | 4,23M | Acquisto | 19,64 | 948,46k | 29,37% |
| 2025-06-06 | JPMorgan Chase & Co.Società | -982,27k | 19,29M | Vendita | 19,64 | 948,46k | -50,88% |
| 2025-06-06 | JPMorgan Chase & Co.Società | -206,00k | 0,00 | Other Disposition | - | 948,46k | -17,84% |
| 2025-06-06 | 55I, LLCSocietà | 13,00 | 255,29 | Acquisto | 19,64 | 26,00 | 100,00% |
Le azioni che visualizzerai appariranno in questo riquadro, così potrai facilmente tornare alle quotazioni di tuo interesse.
Assistenza: support@advfn.it
Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni
Registrati con e-mail
Hai già un account? Accedi
Non hai un account? Registrati
Registrandomi, confermo di aver letto, capito, e accetto i termini e condizioni ADVFN e che sono un investitore privato.
Caratteristiche principali
Premium
